Michele Marchioni1, Petros Sountoulides2, Maida Bada1, Sebastiano Rapisarda3, Cosimo De Nunzio4, Fabiola Raffaella Tamburro5, Luigi Schips1, Luca Cindolo6. 1. Department of Urology, 'SS Annunziata' Hospital, 'G. D'Annunzio' University of Chieti, Chieti, Italy. 2. First Urology Department, Aristotle University of Thessaloniki, Thessaloniki, Greece. 3. Department of Urology, Hospital Gaspare Rodolico, Catania, Italy. 4. Department of Urology, 'Sant'Andrea' Hospital, University La Sapienza, Rome, Italy. 5. Department of Urology, ASL Abruzzo2, 'S. Pio da Pietrelcina' Hospital, Vasto, Italy. 6. Department of Urology, ASL 2 Abruzzo, 'S. Pio da Pietrelcina' Hospital, Vasto, Italy.
Abstract
BACKGROUND: To assess the efficacy and safety of treatment with abiraterone acetate (AA) in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) in the 'real-life' setting. METHODS: Data acquisition on the outcomes of the use of AA in chemotherapy-naive patients with mCRPC was performed by a MEDLINE comprehensive systematic literature search using combinations of the following key words: 'prostate cancer', 'metastatic', 'castration resistant', 'abiraterone', 'real life', and excluding controlled clinical trials (phase II and III studies). Identification and selection of the studies was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria. Outcomes of interest were overall survival (OS), progression-free survival (PFS), 12-week 50% reduction in prostate-specific antigen (PSA), and grade 3 and higher adverse events. Data were narratively synthesized in light of methodological and clinical heterogeneity. RESULTS: Within the eight identified studies that fulfilled the criteria, a total of 801 patients were included in the meta-analysis. Baseline PSA ranged between 9.5 and 212.0 ng/ml. Most of the patients had bone metastases. Duration of treatment with AA was longer in the studies with lower baseline PSA levels. The median OS ranged between 14 and 36.4 months. The PFS, assessed according to different definitions, ranged from 3.9 to 18.5 months. A 50% PSA reduction at 12 weeks was reached by a variable percentage of patients ranging from 36.0% to 62.1%. Finally, the rate of grade 3 and higher adverse events was reported in three studies and ranged from 4.4% to 15.5%. CONCLUSIONS: Despite the high grade of heterogeneity among studies, treatment with AA seems to ensure good survival outcomes in the 'real-life' setting. However, prospective studies based on patients' characteristics being more similar to 'real-life' patients are necessary.
BACKGROUND: To assess the efficacy and safety of treatment with abiraterone acetate (AA) in chemotherapy-naïve men with metastatic castration-resistant prostate cancer (mCRPC) in the 'real-life' setting. METHODS: Data acquisition on the outcomes of the use of AA in chemotherapy-naive patients with mCRPC was performed by a MEDLINE comprehensive systematic literature search using combinations of the following key words: 'prostate cancer', 'metastatic', 'castration resistant', 'abiraterone', 'real life', and excluding controlled clinical trials (phase II and III studies). Identification and selection of the studies was conducted according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis (PRISMA) criteria. Outcomes of interest were overall survival (OS), progression-free survival (PFS), 12-week 50% reduction in prostate-specific antigen (PSA), and grade 3 and higher adverse events. Data were narratively synthesized in light of methodological and clinical heterogeneity. RESULTS: Within the eight identified studies that fulfilled the criteria, a total of 801 patients were included in the meta-analysis. Baseline PSA ranged between 9.5 and 212.0 ng/ml. Most of the patients had bone metastases. Duration of treatment with AA was longer in the studies with lower baseline PSA levels. The median OS ranged between 14 and 36.4 months. The PFS, assessed according to different definitions, ranged from 3.9 to 18.5 months. A 50% PSA reduction at 12 weeks was reached by a variable percentage of patients ranging from 36.0% to 62.1%. Finally, the rate of grade 3 and higher adverse events was reported in three studies and ranged from 4.4% to 15.5%. CONCLUSIONS: Despite the high grade of heterogeneity among studies, treatment with AA seems to ensure good survival outcomes in the 'real-life' setting. However, prospective studies based on patients' characteristics being more similar to 'real-life' patients are necessary.
Authors: Tharsika Manokumar; Salman Aziz; Henriette Breunis; S Faraz Rizvi; Anthony M Joshua; Ian F Tannock; Shabbir M H Alibhai Journal: J Geriatr Oncol Date: 2016-02-04 Impact factor: 3.599
Authors: Ian F Tannock; Ronald de Wit; William R Berry; Jozsef Horti; Anna Pluzanska; Kim N Chi; Stephane Oudard; Christine Théodore; Nicholas D James; Ingela Turesson; Mark A Rosenthal; Mario A Eisenberger Journal: N Engl J Med Date: 2004-10-07 Impact factor: 91.245
Authors: Pasquale Rescigno; David Lorente; Diletta Bianchini; Roberta Ferraldeschi; Michael P Kolinsky; Spyridon Sideris; Zafeiris Zafeiriou; Semini Sumanasuriya; Alan D Smith; Niven Mehra; Anuradha Jayaram; Raquel Perez-Lopez; Joaquin Mateo; Chris Parker; David P Dearnaley; Nina Tunariu; Alison Reid; Gerhardt Attard; Johann S de Bono Journal: Eur Urol Date: 2016-03-07 Impact factor: 20.096
Authors: Larissa Shamseer; David Moher; Mike Clarke; Davina Ghersi; Alessandro Liberati; Mark Petticrew; Paul Shekelle; Lesley A Stewart Journal: BMJ Date: 2015-01-02
Authors: Luca Cindolo; Clara Natoli; Cosimo De Nunzio; Michele De Tursi; Maurizio Valeriani; Silvana Giacinti; Salvatore Micali; Mino Rizzo; Giampaolo Bianchi; Eugenio Martorana; Marcello Scarcia; Giuseppe Mario Ludovico; Pierluigi Bove; Anastasia Laudisi; Oscar Selvaggio; Giuseppe Carrieri; Maida Bada; Pietro Castellan; Stefano Boccasile; Pasquale Ditonno; Paolo Chiodini; Paolo Verze; Vincenzo Mirone; Luigi Schips Journal: BMC Cancer Date: 2017-11-10 Impact factor: 4.430
Authors: Mohammad S Sadaghiani; Sara Sheikhbahaei; Rudolf A Werner; Kenneth J Pienta; Martin G Pomper; Lilja B Solnes; Michael A Gorin; Nae-Yuh Wang; Steven P Rowe Journal: Eur Urol Date: 2021-04-08 Impact factor: 20.096
Authors: G Procopio; V E Chiuri; M Giordano; A R Alitto; R Maisano; R Bordonaro; S Cinieri; S Rossetti; S De Placido; M Airoldi; L Galli; D Gasparro; G M Ludovico; P F Guglielmini; C Carella; P Nova; M Aglietta; L Schips; P Beccaglia; A Sciarra; L Livi; D Santini Journal: ESMO Open Date: 2022-04-08